Mirzaei Reza, Sarkar Susobhan, Dzikowski Lauren, Rawji Khalil S, Khan Lubaba, Faissner Andreas, Bose Pinaki, Yong V Wee
Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.
Departments of Biochemistry and Molecular Biology, Oncology and Surgery, Ohlson Research Initiative and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Oncoimmunology. 2018 Aug 6;7(10):e1478647. doi: 10.1080/2162402X.2018.1478647. eCollection 2018.
The dismal prognosis of glioblastoma is attributed in part to the existence of stem-like brain tumor-initiating cells (BTICs) that are highly radio- and chemo-resistant. New approaches such as therapies that reprogram compromised immune cells against BTICs are needed. Effective immunotherapies in glioblastoma, however, remain elusive unless the mechanisms of immunosuppression by the tumor are better understood. Here, we describe that while the conditioned media of activated T lymphocytes reduce the growth capacity of BTICs, this growth suppression was abrogated in live co-culture of BTICs with T cells. We present evidence that BTICs produce the extracellular matrix protein tenascin-C (TNC) to inhibit T cell activity in live co-culture. In human glioblastoma brain specimens, TNC was widely deposited in the vicinity of T cells. Mechanistically, TNC inhibited T cell proliferation through interaction with α5β1 and αvβ6 integrins on T lymphocytes associated with reduced mTOR signaling. Strikingly, TNC was exported out of BTICs associated with exosomes, and TNC-depleted exosomes suppressed T cell responses to a significantly lesser extent than control. Finally, we found that circulating exosomes from glioblastoma patients contained more TNC and T cell-suppressive activity than those from control individuals. Taken together, our study establishes a novel immunosuppressive role for TNC associated with BTIC-secreted exosomes to affect local and distal T lymphocyte immunity.
胶质母细胞瘤的预后不佳,部分原因是存在具有高度放射和化学抗性的干细胞样脑肿瘤起始细胞(BTICs)。需要新的方法,比如重新编程受损免疫细胞以对抗BTICs的疗法。然而,除非能更好地理解肿瘤的免疫抑制机制,否则胶质母细胞瘤的有效免疫疗法仍难以实现。在此,我们描述了虽然活化T淋巴细胞的条件培养基会降低BTICs的生长能力,但在BTICs与T细胞的活共培养中,这种生长抑制作用被消除了。我们提供的证据表明,在活共培养中,BTICs会产生细胞外基质蛋白腱生蛋白-C(TNC)来抑制T细胞活性。在人类胶质母细胞瘤脑标本中,TNC广泛沉积在T细胞附近。从机制上讲,TNC通过与T淋巴细胞上的α5β1和αvβ6整合素相互作用来抑制T细胞增殖,这与mTOR信号传导减少有关。令人惊讶的是,TNC与外泌体一起从BTICs中输出,且TNC缺失的外泌体对T细胞反应的抑制程度明显低于对照组。最后,我们发现胶质母细胞瘤患者的循环外泌体比对照组个体的含有更多的TNC和T细胞抑制活性。综上所述,我们的研究确立了与BTIC分泌的外泌体相关的TNC的一种新的免疫抑制作用,以影响局部和远端T淋巴细胞免疫。